Frontlight ResearchEarly access
TerminatedPhase 1
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
Key facts
- Who runs it
- OncoTherapy Science, Inc.
- Where
- Japan3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 12 people enrolled
- Started
- 10 Jan 2020
- Ended
- 11 Jan 2024
- Type of study
- Interventional
- Treatments tested
- OTSA101-DTPA-111In
- OTSA101-DTPA-90Y
- Record updated
- 2 February 2024
- Why it stopped
- Some of the raw materials for the investigational drug are difficult to obtain and expensive.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Patients with a documented relapsed or refractory synovial sarcoma after standard chemotherapy
- Patients ≥18 years of age at the time of obtaining informed consent
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Patients with measurable lesion
- Patients not received any anti-malignancy agent or specified surgical intervention within 28 days or specified radiotherapy within 14 days prior to study registration
- Patients without any clinically significant laboratory abnormality
- Patients with adequate heart function as measured by echocardiography or multiple gated acquisition scan (MUGA)
- Patients with adequate pulmonary function as measured by pulmonary function tests
- Patients who are either not of childbearing potential or who agree to use a contraception method during the study and for 12 months after the last dose of study drug
- Patients must be able to understand and be willing to sign a written informed consent
Who cannot take part
- Patients with documented concurrent malignancy
- Patients with myocardial infarction (MI) within 6 months prior to study registration
- Patients with any infection requiring systemic treatment
- Patients with a known history of autoimmune diseases
- Patients with uncontrolled diseases
- Patients with any disease requiring continuous systemic administration of steroids or immunosuppressants
- Patients with evidence of active HBV, HCV or HIV infection
- Patients with psychiatric disorders and is considered to have difficulty to study participation
- Patients with a known history of hypersensitivities to antibody agents or serum albumin agents
- Patients with brain metastasis with clinical symptoms
- Patients with lung inflammation or pulmonary fibrosis
- Pregnant or breastfeeding female patients, or female patients with suspected pregnancy
- Patients who are participating any other investigational treatments during the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate safety and pharmacokinetics as well as the biodistribution of OTSA101-DTPA-111In and to evaluate the safety of intravenous administration of OTSA101-DTPA-90Y.
The group in the trial
- Single Study Arm, no competitorTreatment being tested
Treatment: OTSA101-DTPA-111In and OTSA101-DTPA-90Y
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial Sarcoma
- Publications
- Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer.Journal of translational medicine, 2024
- Record updated
- 2 February 2024